Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alebund Pharmaceuticals (Jiangsu)'s total inventories for the quarter that ended in Dec. 2025 was HK$11.34 Mil. Alebund Pharmaceuticals (Jiangsu)'s average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Dec. 2025 was HK$8.94 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Alebund Pharmaceuticals (Jiangsu)'s Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$-0.98.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Alebund Pharmaceuticals (Jiangsu)'s Days Inventory for the
six
months ended in Dec. 2025 was 86.29.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Alebund Pharmaceuticals (Jiangsu)'s Inventory Turnover for the quarter that ended in Dec. 2025 was 2.11.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alebund Pharmaceuticals (Jiangsu)'s Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.26.
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Alebund Pharmaceuticals (Jiangsu)'s Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Alebund Pharmaceuticals (Jiangsu)'s Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Alebund Pharmaceuticals (Jiangsu) Total Inventories Related Terms
Alebund Pharmaceuticals (Jiangsu) Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alebund Pharmaceuticals (Jiangsu) Total Inventories Chart
Alebund Pharmaceuticals (Jiangsu) Annual Data
Trend
Dec24
Dec25
Total Inventories
6.53
11.34
Alebund Pharmaceuticals (Jiangsu) Semi-Annual Data
Alebund Pharmaceuticals (Jiangsu) Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of HK$11.34 Mil mean?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a Total Inventories of HK$11.34 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Alebund Pharmaceuticals (Jiangsu) and its competitors.
Is Alebund Pharmaceuticals (Jiangsu)'s Total Inventories too high?
Alebund Pharmaceuticals (Jiangsu)'s current Total Inventories is HK$11.34 Mil. Overall, Alebund Pharmaceuticals (Jiangsu) has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Alebund Pharmaceuticals (Jiangsu)'s Total Inventories compare to LLY and JNJ?
Alebund Pharmaceuticals (Jiangsu)'s Total Inventories of HK$11.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Alebund Pharmaceuticals (Jiangsu) and its competitors. Alebund Pharmaceuticals (Jiangsu)'s current Total Inventories is HK$11.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alebund Pharmaceuticals (Jiangsu) stock overvalued right now?
Alebund Pharmaceuticals (Jiangsu) (HKSE:09637) has a current Total Inventories of HK$11.34 Mil. The current Total Inventories is HK$11.34 Mil. Alebund Pharmaceuticals (Jiangsu)'s overall GF Score™ is 5/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Alebund Pharmaceuticals (Jiangsu) (HKSE:09637), the current Total Inventories is HK$11.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alebund Pharmaceuticals (Jiangsu) Ltd is a biopharmaceutical company. Along with its subsidiaries, the company is principally engaged in the development, manufacturing, and commercialization of renal products. Its product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The company generated revenue from the sales of Mircera in China, a product used in the treatment of renal anemia.
5GF Score
Get the complete analysis for HKSE:09637
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09637 has been successfully added to your 
